C12N 2770/24134
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/24134 (Use of virus or viral component as vaccine) appears on 519 US grants and 787 published applications in this corpus.
Search patents in C12N- Granted patents
- 519
- Published applications
- 787
- Assignees
- 362
- Inventors
- 1,293
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 2 | 0 |
| 2000 | 5 | 0 |
| 2001 | 6 | 0 |
| 2002 | 4 | 1 |
| 2003 | 8 | 5 |
| 2004 | 2 | 12 |
| 2005 | 4 | 12 |
| 2006 | 3 | 7 |
| 2007 | 4 | 24 |
| 2008 | 7 | 15 |
| 2009 | 9 | 21 |
| 2010 | 15 | 25 |
| 2011 | 11 | 29 |
| 2012 | 16 | 29 |
| 2013 | 12 | 18 |
| 2014 | 29 | 28 |
| 2015 | 20 | 32 |
| 2016 | 16 | 39 |
| 2017 | 19 | 47 |
| 2018 | 36 | 50 |
| 2019 | 38 | 72 |
| 2020 | 46 | 66 |
| 2021 | 42 | 63 |
| 2022 | 50 | 44 |
| 2023 | 35 | 51 |
| 2024 | 34 | 46 |
| 2025 | 28 | 32 |
| 2026 | 11 | 19 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Live-attenuated flaviviruses with heterologous antigens22 Sep 2026US 12,741,991 B2Katholieke Universiteit Leuven
- Compositions and methods for stabilizing flaviviruses with improved formulations15 Sep 2026US 12,734,230 B2Takeda Vaccines, Inc.
- Zika/dengue vaccine and application thereof2 Jun 2026US 12,642,846 B2Institute of Microbiology, Chinese Academy of Sciences
- Methods and compositions for recombinant dengue viruses or vaccine and diagnostic development14 Apr 2026US 12,600,752 B2The University of North Carolina at Chapel Hill
- Vaccines against Powassan virus, and methods of using same17 Mar 2026US 12,576,144 B2The Wistar Institute of Anatomy and Biology
- Systems and Methods for Delivery of Viral Antigens8 Oct 2026US 2026/0306610 A1Veergen Inc.
- Dengue virus serotype-specific modulation of t cell responses8 Oct 2026US 2026/0306621 A1The United States Government as represented by the Department of Veterans Affairs
- A novel non-stoichiometric multi-element adjuvant (nsma) and composition thereof8 Oct 2026US 2026/0306624 A1Magvitae Innovations Inc
- Human antibodies targeting zika virus ns1, ns1 polypeptides and uses thereof10 Sep 2026US 2026/0266820 A1Icahn School of Medicine at Mount Sinai
- Dengue vaccine3 Sep 2026US 2026/0256903 A1VLP Therapeutics, LLC
Most cited
By later US patents
- Method of potentiating an immune response425US 5,075,109 ASouthern Research Institute · 1991
- Process for the production of virus vaccine116US 4,659,569 AKabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo · 1987
- Zika virus RNA vaccines108US 10,124,055 B2ModernaTX, Inc. · 2018
- High potency immunogenic zika virus compositions92US 10,273,269 B2ModernaTX, Inc. · 2019
- Zika RNA vaccines85US 10,449,244 B2ModernaTX, Inc. · 2019